"Immunotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection.
| Descriptor ID |
D007167
|
| MeSH Number(s) |
E02.095.465.425
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Immunotherapy".
Below are MeSH descriptors whose meaning is more specific than "Immunotherapy".
This graph shows the total number of publications written about "Immunotherapy" by people in this website by year, and whether "Immunotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 |
| 1998 | 0 | 2 | 2 |
| 1999 | 2 | 1 | 3 |
| 2000 | 1 | 3 | 4 |
| 2001 | 2 | 4 | 6 |
| 2002 | 3 | 3 | 6 |
| 2003 | 3 | 4 | 7 |
| 2004 | 5 | 7 | 12 |
| 2005 | 2 | 3 | 5 |
| 2006 | 5 | 2 | 7 |
| 2007 | 4 | 1 | 5 |
| 2008 | 7 | 5 | 12 |
| 2009 | 4 | 2 | 6 |
| 2010 | 7 | 5 | 12 |
| 2011 | 5 | 5 | 10 |
| 2012 | 8 | 7 | 15 |
| 2013 | 8 | 10 | 18 |
| 2014 | 9 | 10 | 19 |
| 2015 | 9 | 18 | 27 |
| 2016 | 20 | 2 | 22 |
| 2017 | 21 | 6 | 27 |
| 2018 | 32 | 16 | 48 |
| 2019 | 31 | 17 | 48 |
| 2020 | 21 | 27 | 48 |
| 2021 | 21 | 23 | 44 |
| 2022 | 4 | 29 | 33 |
| 2023 | 4 | 34 | 38 |
| 2024 | 25 | 28 | 53 |
| 2025 | 28 | 12 | 40 |
| 2026 | 12 | 6 | 18 |
To return to the timeline,
click here.
Below are the most recent publications written about "Immunotherapy" by people in Profiles.
-
Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC. Nat Med. 2026 Sep; 32(9):3235-3247.
-
NCCN Guidelines® Insights: Esophageal and Esophagogastric Junction Cancers, Version 4.2026. J Natl Compr Canc Netw. 2026 Sep; 24(9).
-
Small-Cell Lung Cancer: Biology, Translational Science and Clinical Innovation. Drugs. 2026 Sep; 86(9):1513-1533.
-
Engineered probiotic Bifidobacterium for tumor-targeted pancreatic cancer therapy. Sci Adv. 2026 Jul 24; 12(30):eadz1388.
-
Neoadjuvant Stereotactic Body Radiotherapy plus Immune Therapy Favorably Remodels the Hepatocellular Carcinoma Tumor Microenvironment. Clin Cancer Res. 2026 Jul 17; 32(14):2885-2897.
-
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression: A Systematic Review and Meta-Analysis. JAMA Oncol. 2026 Jul 01; 12(7):753-761.
-
Claudin18.2 and the PD-1/PD-L1 axis in gastric cancer: mechanistic insights and implications for combination immunotherapy. J Transl Med. 2026 06 26; 24(1).
-
Tumor cell ferroptosis in antitumor immunity and immunotherapy efficacy. J Immunother Cancer. 2026 Jun 19; 14(6).
-
The IMMUNO-BIOMAP trial in NSCLC: An adaptive multimodal framework for biomarker-guided care. Cell Rep Med. 2026 Jun 16; 7(6):102790.
-
Mitochondrial potential reflects T cell fitness and function during cancer immunotherapy. J Immunol. 2026 Jun 07; 215(6).